A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)

Inclusion Criteria:

• Gradual and progressive change in cognitive function ≥6 months prior to screening.

• A Mini-Mental (MMSE) score of 20 to 30 (inclusive) at screening.

• Has an amyloid PET scan result consistent with the eligibility criteria.

• Have a reliable study partner who will provide written informed consent toparticipate and is in frequent contact with the participant.

• Have adequate literacy, vision, and hearing for the neuropsychological testing inthe opinion of the investigator at the time of screening.

• Are reliable and willing to make themselves available for the duration of the studyand are willing to follow study procedures.

• Males and females will be eligible for this study.

• Women not of childbearing potential (WNOCBP) may participate in this trial.

Exclusion Criteria:

• Current serious or unstable illnesses that, in the investigator's opinion, couldinterfere with the analyses in this study; or has a life expectancy of <24 months.

• History of cancer with high risk of recurrence and preventing completion of thetrial.

• Participants with any current primary psychiatric diagnosis other than AD that inthe investigator's opinion, is likely to confound interpretation of the drug effect,affect cognitive assessment, or affect the participant's ability to complete thestudy.

• History of clinically significant multiple or severe drug allergies.

• Have any clinically important abnormality at screening, as determined byinvestigator that could be detrimental to the participant, could compromise thestudy, or show evidence of other etiologies for dementia.

• Screening magnetic resonance imaging (MRI) which shows evidence of significantabnormality that would suggest another potential etiology for progressive dementiaor a clinically significant finding that may impact the participant's ability tosafely participate in the study.

• Have any contraindications for MRI or positron emission tomography (PET).

• Have had prior treatment with a passive anti-amyloid immunotherapy.

• Have received active immunization against Aβ in any other study.

• Have known allergies to remternetug related compounds, or any components of theformulation.